1. Figure 4 from Vigne et al. (2017; see below) depicts results of phase II and

Question

1. Figure 4 from Vigne et al. (2017; see below) depicts results of phase II and phase III clinical trials evaluating the immunogenicity of the tetravalent dengue vaccine (CYD-TDV) among patients with (seropositive) and without (seronegative) previous exposure to DENV. Do results presented here support the claim that the tetravalent vaccine is immunogenic for both seropositive and seronegative individuals? Explain.

YD14) b) Dengue seropostive 2-B y group (CYD14 Dengue seronegative 2-8 y group Time Time d) Dengue seropositive 9-14 y group (CYD14) c Dengue seronegative 9-14 y group (CYD14 2y Pre-dose Pre-dlose Time Time Derg seropostivo 9-16 y group CYD15) Dengue seronegative 9-16 y group (CYD15 2 y 3 y 2 y 8 y 9 y in the CYD14 and CYD15 studies Figure 4. GMTs (95%C) fr each dengue serotype over tirme (yeas after the last dose) in children aged 2-8 y or

Explanation / Answer

Yes , the vaccination is effective for both seropositive and seronegative individuals. Over all, after vaccination of 3rd dose , the geometric mean titre which reflects the antibody response is low after 3rd dose and between 1 to 2 years. After 2 years the antibody response is higher in all age groups irrespective for their age . For the seronegative patients who are in control group (Placebo) , the antibody response is high throughout their followup after 3rd dose. But in seropositive patients in placebo group , initially they have low antibody response and after 2 years their response remains higher in age group less than 9 years. The antibody response is higher in seropositive patients of age above 9 years aompared to below 9 years patients.

Related Questions

Navigate

• Browse (All)
• Browse 1
• Subjects

---

---

Integrity-first tutoring: explanations and feedback only — we do not complete graded work. Learn more.